Hebei yanxi chemical co.,LTD.
Country: China (Mainland)
Year Established: 2017
Business License:
Business type: Manufacturers
Product Certificate:(1)
- Production License
Contact Details | Similar Products

Ms.faithe
Mr.peter
Mr.korol
Ms.nina
Ms.noa

Communicate with Supplier:

: Ms. xing: What can I do for you?

Oxaliplatin Pharma API Paclitaxel Treatment of colorectal cancer CAS NO.61825-94-3 CAS NO.61825-94-3

MSDS/COA Download

FOB Price:: USD 1.00-3.00 /Kilogram Get Latest Price

Min.Order Quantity:: 1 Kilogram

Purity:: 99%

Port:: Qingdao port

Payment Terms:: T/T,Other

Add to Inquiry Cart

Product Details

Keywords

Oxaliplatin
Oxaliplatin supplier
61825-94-3

Quick Details

ProName: Oxaliplatin Pharma API Paclitaxel Trea...
CasNo: 61825-94-3
Molecular Formula: C8H14N2O4Pt
Appearance: crystal, powder
Application: Pharmaceutical intermediates
DeliveryTime: 1-2 days
PackAge: as your request
Port: Qingdao port
ProductionCapacity: 10 Kilogram/Day
Purity: 99%
Storage: stay in dry, cool and well-sealed
Transportation: EMS,HK EMS,FEDEX,DHL,TNT
LimitNum: 1 Kilogram
Moisture Content: 0.01%
Impurity: 0.001%
Loss On Drying: 0.2%
Melting Point: 177℃ ~ 181℃
Specific Rotation: +27°
Assay: 99.2%

Superiority

reason for choosing us:

1): superior quality and competitive price:

our company is a renowned pharmaceutical manufacturer with more than 15 years experiences in china and all powders are supplying from our factory directly.

2): fast ,safe and well disguised delievery:

well-trained and disciplined packing team and sufficient stock ensure the parcel can be delieveried to your hand fastly and safely by dhl, tnt, fedex, hkems, ups, etc.

3): experienced in exporting:

we have clients throughout the world. products have been exported to germany, norway, poland, finland, spain, uk, france, russia, usa, brazil, mexico, australia, japan, korea, thailand, indonesia, uruguay and many other countries. custome pass rate ≥99%

4): flexible payment terms:

t/t,,money gram,bitcoin. there will always be a term that is convient to you.

5): warmhearted customer service and after-sale service:

the parcel's photos and tracking numbers will be sent to you once it is prepared. any of your questions would be solved for the first as soon as possible.

Details

quick details

proname: oxaliplatin pharma api paclitaxel tre...
casno: 61825-94-3
molecular formula: c8h14n2o4pt
appearance: white powder
application: pharmaceutical raw intermediates
deliverytime: within 10 days after receiving the pay...
package: a variety of packaging methods suitabl...
port: wuhan / shanghai / guangzhou ...
productioncapacity: 1000 metric ton/month
purity: 99%
storage: dry, dark and ventilated place
transportation: ems, hkems, dhl, tnt, ups, fedex.... ...
limitnum: 10 gram

superiority

1. hubei jusheng technology co., ltd., is a global chemical industry manufacturers and suppliers of pharmaceuticals and intermediates in china.

2. the yearly production capacity is 50000mt, 80% for export.we have a professinal export team. both by air and by sea,we ensure that we meet the customer expectations with promptness.

3. our company facing global high-tech pharmaceutical raw materials, high complex new type intermediates, fine chemicals custom synthesis, scale-up production and rare chemicals trade. corey have well-equipped machine, strong technical force and considerate marketing team service.

4. we also have rich experience advantage in basic research, small scale process development, scale-up, industrial technology development & production and cost control.

details

oxaliplatin basic information

adverse reactions and side effects production method

product name:	oxaliplatin
synonyms:	[sp-4-2-(1r-trans)]-(1,2-cyclohexanediamine-n,n')[ethanedioata(2-)-o,o']platinum;oxaliplatin;trans-l-diaminocyclohexane oxalatoplatinum;(1,2-cyclohexanediamine-n,n’)(ethanedioato(2-)-o,o’)-platinu(sp-4-2-(1r-tr;1-ohp;oxalato(1r,2r-cyclohexanediammine)platinum(ii);oxalatoplatin;oxalatoplatinum
cas:	61825-94-3
mf:	c8h14n2o4pt
mw:	397.29
einecs:	274-613-9
product categories:	pharmaceutical material and intermeidates;active pharmaceutical ingredients;antineoplastic;intermediates & fine chemicals;pharmaceuticals;apis;amines;heterocycles;chemical reaction,pharm,electronic,materials;praxilene;inhibitors

oxaliplatin chemical properties

storage temp.	store at +4°c
form	solid
stability:	stable. store cool. incompatible with oxidizing agents.

safety information

hazard codes	xn,xi
risk statements	36/37/38-40-42/43
safety statements	26-36
ridadr	2811
wgk germany	3
rtecs	tp2275850
hazardclass	6.1(a)
packinggroup	ii

msds information

provider	language
sigmaaldrich	english

oxaliplatin usage and synthesis

treatment of colorectal cance	oxaliplatin belongs to platinum derivatives for the treatment of patients with colorectal cancer metastasis after the failure of the clinical treatment through fluorouracil , it can be used alone or in combination with the use of fluorouracil, it is the third generation of new class of anti-tumor platinum compounds for colorectal cancer after cisplatin and carboplatin , and so far it has been the only envelope platinum drug which has a significant activity. the principle is by producing alkylation conjugate to act on dna, to form crosslinks within the chain and between the chain which inhibit dna synthesis and replication.at the same time, it can inhibit the hyperplasia of ovarian cancer and melanoma cell lines. august 2002, the us food and drug administration (fda) approved the sanofi saint raborg company's anticancer drug oxaliplatin (, eloxatin) for the second-line treatment of metastatic colon cancer. january 2004, the us food and drug administration (fda) formally approved the injection of oxaliplatin (eloxatin) and 5-fluorouracil (5fu) and leucovorin (lv) joint (folfox program) for the first-line treatment of advanced colorectal cancer. the domestic market is currently dominated by sanofi - aventis (eloxatin); jiangsu hengrui medicine co., ltd. (oxaliplatin); jiangsu nanjing pharmaceutical (austrian platinum) three manufacturers monopoly, which occupy more than 85% of the domestic market share .
adverse reactions and side effect	1, the hematopoietic system: oxaliplatin has some hematologic toxicity. when administered alone,it can cause the following adverse reactions: anemia, leukopenia, neutropenia, thrombocytopenia, sometimes up to grade 3 or 4. when in combination with 5-fluorouracil , neutropenia and thrombocytopenia diseases’ hematological toxicity increases . 2, the digestive system:when administered alone, it can cause nausea, vomiting, diarrhea. these symptoms sometimes are very serious. when in combination with 5-fluorouracil, these side effects are increased significantly. it is recommended to give preventive and / or therapeutic anti-emetic medication . 3,the nervous system: peripheral neuritis, characterized by peripheral sensory neuropathy. sometimes there are accompanied around the mouth, upper respiratory tract and upper digestive tract spasms and sensory disorders. the above information is edited by the chemicalbook of tian ye.
chemical propertie	triangular flaky colorless crystals. the water solubility is 7.9mg / ml.
	for the treatment of colorectal cancer.
production metho	5g of trans-cyclohexanediamine and 18g k2 (ptcl4) aqueous solution react at room temperature for 12h, to give 12g intermediate product (i). 6: 8g of silver nitrate is added to 3g compound (i) aqueous solution , the mixture is stirred for 2 ~ 3h under the dark, then add 4.8g oxalic acid dipotassium salt, react for 8h at room temperature , oxaliplatin is obtained .
chemical properties	white crystalline solid
usage	third generation platinum complex. an antitumor agent with activity against colorectal cancer. cytotoxicity follows the formation of adducts with dna. antineoplastic.
usage	vasodilator
usage	a antitumor agent with activity against colorectal cancer. cytotoxicity follows the formation of adducts with dna
biological activity	antitumor agent that forms platinum-dna adducts. causes intra- and interstrand dna crosslinks blocking dna replication and transcription. displays higher cytotoxicity and lower nephrotoxicity than analog cisplatin (cis-diaminodichloroplatinum ) and shows antitumor activity in cell lines with acquired cisplatin resistance.